Context Therapeutics Inc. — Form 8-K Summary
Business Context and Reporting Period
Context Therapeutics Inc. filed a Form 8-K dated June 2, 2022, reporting the results of its Annual Meeting of Stockholders held that day. The filing does not provide quarterly or annual operating results.
Key Financial Metrics
The filing does not provide revenue, profit, cash flow, margins, debt, liquidity, or other financial performance metrics.
Material Changes Versus Prior Period
No material financial or operating changes versus a prior comparable period are reported.
Meeting Results, Outlook, and Risks
- As of the April 4, 2022 record date, 15,966,053 common shares were issued and outstanding and entitled to vote.
- Shares present or represented by proxy totaled 9,161,941, or approximately 57.38%, constituting a quorum.
- Stockholders ratified the appointment of CohnReznick LLP as the independent registered public accounting firm for the year ending December 31, 2022.
- Voting results were 9,144,524 for, 8,877 against, and 8,540 abstentions; no broker non-votes were reported.
- The filing contains no management guidance, outlook, contingencies, unusual items, or specific risk disclosures.
Investor Verification Items
- Verify the appointment and engagement of CohnReznick LLP for the 2022 fiscal year.
- Review subsequent filings for financial results, financing activity, cash runway, and other developments not addressed in this 8-K.
- Confirm the voting totals and quorum information against the definitive proxy statement and meeting disclosures.